Clinical trials: Prostate Cancer Detection
Prostate Cancer Recurrent
PET-MR-PSA Prostate Cancer Recidive Study
Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging…
- Trial name
- PET-MR-PSA (NCT02562131)
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer (Post Prostatectomy)
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy.
- Trial name
- Co-PSMA (NCT06907641)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- St Vincent's Hospital, Sydney
Infection
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora.
- Trial name
- PREVENT (NCT04843566)
- Testing
- Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
- Where
- 10 sites in United States
- Volunteers
- 687 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness
The purpose of this study is to develop, validate, and evaluate the correlation of novel magnetic resonance imaging (MRI) methods with prostate cancer aggressiveness and histological data obtained during prostatectomy.
- Trial name
- PROAG (NCT02545881)
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Prostate Cancer
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per…
- Trial name
- PROSTEP-002 (NCT04655365)
- Testing
- Enzalutamide capsule
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection
The goal of this clinical trial is to learn if a new ultrasound-based imaging method (PCaVision) can accurately detect clinically significant prostate cancer in adult men (18 years and older) who are either undergoing initial…
- Trial name
- PCaVISTA (NCT06935487)
- Testing
- transrectal ultrasound of prostate (TRUS) with AI software algorithm, MRI prostate
- Where
- 10 sites in France, Germany and 4 more
- Volunteers
- 806 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate-Specific Antigen
Adequacy of Prostate-Specific Antigen (PSA) Requests
Objectives. The primary aim of this study is to evaluate the characteristics of the determination of PSA for the early detection of prostate cancer or in the presence of symptoms, in general practice in two health departments of…
- Trial name
- NCT03968692
- Testing
- Prostate-Specific Antigen test
- Where
- 2 sites in Spain
- Volunteers
- 1,410 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Prostate Cancer
Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation
Men meeting local clinical standard of care to undergo a prostate MRI for suspicion of prostate cancer will be included. Blood sample will be drawn on the day of MRI or immediately prior to MRI for measurement of the prostate…
- Trial name
- S3M-MRI (NCT06573736)
- Testing
- Stockholm3
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Prostate Cancer
Optical Tomography in Prostate Cancer
This study is looking to see if a new device, diffuse optical tomography (DOT), can detect prostate cancer. The investigators will also see if DOT can tell the difference between high risk and low risk prostate cancers.
- Trial name
- NCT03215992
- Testing
- Diffuse Optical Tomography (DOT) System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Columbia University
Prostate Cancer
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.
- Trial name
- FLUPROSTIC (NCT01501630)
- Testing
- performance of PET/CT and whole-body MRI
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
Multiparametric MRI of the prostate (mpMRI) plays an integral role in contemporary prostate cancer management. It involves the acquisition of both anatomical sequences (T1- and T2-weighted images) as well as 'functional' imaging…
- Trial name
- NCT05046782
- Testing
- restriction spectrum imaging (RSI)
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Organoid
Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis
This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on…
- Trial name
- NCT06536725
- Testing
- Building Organoid-on-chips models
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
Prostate Cancer, Recurrent Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low…
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent
- Trial name
- NCT07593079
- Testing
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer, 18F- Fluorocholine
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
The present study in patients with Prostate cancer and biochemical failure after surgery and/or radical-postoperative Radio Therapy (RT) will evaluate if PET/CT with 18F-JK-PSMA-7 compared to PET-CT 18F-Choline is able to…
- Conditions
- Prostate Cancer, 18F- Fluorocholine, PSMA PET, Radiotherapy
- Trial name
- MIP7 (NCT05622162)
- Testing
- Radiopharmaceutical 18F-JK-PSMA-7, Radiopharmaceutical 18F-Fluorocholine
- Where
- 2 sites in Italy
- Volunteers
- 106 people
- Sponsor
- ITEL Telecomunicazioni Srl
Prostate Carcinoma
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater than or equal to 2 ng/mL.
- Trial name
- NCT04910425
- Testing
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Sponsor
- Northwestern University
Castration-resistant Metastatic Prostate Cancer, Treated by 177Lutetium-PSMA-617 (Lu-PSMA)
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
Prostate cancer is the most common cancer in men. Its incidence is rising as the population ages. In the localized stage, the 5-year overall survival rate (OS) is 98%.
- Trial name
- PSMA-PRED (NCT06600802)
- Testing
- Blood samples
- Where
- 5 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Jean Perrin
Prostate Cancer
Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint
This is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.
- Trial name
- NCT01394042
- Testing
- Proxiscan device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Radiological Associates of Sacramento Medical Group Inc.
Prostatic Neoplasms, Recurrence
PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer
The aim of this study is to evaluate PSMA-PET for the detection of occult biological recurrence in patients with prostatic cancer referred to the Brest University Hospital.
- Trial name
- RB-PSMA (NCT04983459)
- Where
- France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Prostatic Neoplasm
Detection Rate of Prostate Cancer in Men Undergoing MRI
To assess prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging (MRI) before planning prostate biopsy. Results will be stratified considering men with/without previous negative prostate biopsy.
- Trial name
- NCT04398173
- Testing
- multiparametric MRI
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia